SWTX लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 3849 min ago

@ $44.56

जारी किया गया: 4 May 2024 @ 01:15

वापसी: 1.23%

पिछला सिग्नल: May 3 - 22:32

पिछला सिग्नल: खरीदें

वापसी: 1.03 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 01:30):

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...

Stats
आज की मात्रा	1.50M
औसत मात्रा	1.17M
बाजार मूल्य	3.34B
EPS	$-1.450 ( 2024-05-02 )
अगली कमाई की तारीख	( $-1.170 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.76
ATR14	$2.98 (6.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ashar Bhavesh	Sell	1 824	Common Stock
2024-02-16	Pichl Daniel	Buy	15 000	Common Stock
2024-02-16	Pichl Daniel	Sell	15 000	Common Stock
2024-02-16	Pichl Daniel	Sell	15 000	Stock Option (Right to Buy)
2024-02-02	Ashar Bhavesh	Sell	1 089	Common Stock

INSIDER POWER
26.21
Last 99 transactions
Buy: 2 487 277 \| Sell: 1 935 911

मात्रा सहसंबंध

लंबा: 0.90 (very strong)

छोटा: 0.57 (weak)

Signal:(79) Neutral

Springworks Therapeutics सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
PAE	0.92
SY	0.918
TIL	0.917
CLBT	0.916
FXCO	0.915
SLN	0.914
SCR	0.914
CMPO	0.914
TNYA	0.913
ALGM	0.911

10 सबसे अधिक नकारात्मक सहसंबंध
BFRI	-0.916
TUEM	-0.915
VALN	-0.911
SVOK	-0.909
RTPY	-0.901
NAKD	-0.9
CYTO	-0.897
RMRM	-0.896
PROC	-0.895
LCAP	-0.883

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Springworks Therapeutics सहसंबंध - मुद्रा/वस्त्र

-0.07
( neutral )

0.24
( neutral )

0.00
( neutral )

-0.38
( neutral )

-0.39
( neutral )

0.54
( weak )

Springworks Therapeutics वित्तीय

Annual	2023
राजस्व:	$5.45M
सकल लाभ:	$5.03M (92.25 %)
EPS:	$-5.15

FY	2023
राजस्व:	$5.45M
सकल लाभ:	$5.03M (92.25 %)
EPS:	$-5.15

FY	2022
राजस्व:	$6.15M
सकल लाभ:	$4.25M (69.16 %)
EPS:	$-5.14

FY	2021
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-4.02

Financial Reports:

No articles found.

Springworks Therapeutics

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.